

**IN THE CLAIMS:**

1. (Previously presented) A pharmaceutical composition comprising a virus, said virus comprising a recombinant adeno-associated virus vector comprising at least two adeno-associated virus inverted terminal repeats, a promoter/regulatory sequence, isolated DNA encoding Factor IX and accompanying 5' and 3' untranslated regions and a transcription termination signal.
2. (Previously presented) The composition of claim 1, further comprising a portion of intron 1 of a Factor IX gene.
3. (Previously presented) The composition of claim 2, wherein said portion of intron 1 of a Factor IX gene is from about 0.3 kb to about 1.7 kb in length.
4. (Previously presented) The composition of claim 1, wherein said isolated DNA encoding Factor IX comprises a mutation encoding an alanine residue in place of lysine in the fifth amino acid position from the beginning of mature F.IX which renders Factor IX encoded thereby incapable of binding to collagen IV.
5. (Cancelled)
6. (Previously presented) The composition of claim 1 further comprising a pharmaceutically acceptable carrier.
7. (Previously presented) The composition of claim 1, wherein said promoter/regulatory sequence comprises the cytomegalovirus immediate early promoter/enhancer.
8. (Previously presented) The composition of claim 1, wherein said transcription termination signal is the SV40 transcription termination signal.
9. (Previously presented) A kit including the virus of claim 1.
- 10.-28. (Cancelled)